PF 4447943

Drug Profile

PF 4447943

Alternative Names: PDE9i; PF-04447943; PF-4447943

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Neuropsychotherapeutics
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sickle cell anaemia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in Sickle cell anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Oct 2016 Pfizer completes a phase I trial in Sickle cell anaemia (In volunteers) in USA (NCT02785770)
  • 01 Sep 2016 Pfizer completes a phase I trial in Sickle cell anaemia in USA, Belgium, Italy, the Netherlands and United Kingdom (PO) (NCT02114203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top